Navigation Links
IDIS Opens New American Office in Response to Industry's Growing Need for Pre-Launch Named Patient Programs
Date:8/26/2008

LONDON, Aug. 26 /PRNewswire/ -- IDIS, the world leader in the development and implementation of pre-launch Named Patient Programs (NPPs), announces the opening of a new regional office in Iselin, New Jersey, USA. This office places IDIS in a stronger position to support US based pharmaceutical companies in the implementation of programs to support early access of their medicines.

NPPs provide drug developers across the world with a legal and ethical way to make medicines available where appropriate, in response to requests made by physicians, when those medicines are not yet approved in their country or in late-stage clinical trials. The programs that IDIS establishes in partnership with pharmaceutical and biotechnology companies must adhere to the strict regulatory guidelines of the country from which the request originates to allow patients, who have a genuine unmet medical need, with access to potentially life-saving medicines.

The Iselin office will be headed by John Lagus, Vice President of Business & Corporate Development, IDIS, who is leading the expansion of IDIS in the US.

John Lagus said: "This expansion is critical for building our presence in the US for all our global partners, as well as providing proximity to the pharmaceutical and biotechnology companies based in the US. This new office demonstrates IDIS' commitment to our clients, who requested we establish a US presence, and helps the business to further deliver global market access for the pharmaceutical and biotechnology industry through named patient programs, as well as comparator drug sourcing."

In support of companies sponsoring comparative effectiveness clinical trials, IDIS has built expertise in the strategy for and the procurement of comparator drugs. IDIS has a dedicated procurement team that is focused exclusively on identifying reputable sources for comparator drugs from around the world, achieved as a result of extensive and long-running relationships with drug manufacturers.

About IDIS ...

Founded in the UK in 1987, IDIS expanded into Europe six years later, with US pharmaceutical and biotechnology strategic partners established in the last 10 years. IDIS is the world leader in the development and implementation of NPPs.

IDIS is headquartered near central London.

Visit the IDIS website at http://www.idispharma.com.

Contact: Lynn Blenkhorn of Feinstein Kean Healthcare, +1-508-851-0930


'/>"/>
SOURCE IDIS
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cartesian Gridspeed Opens Subsidiary Operation in North America
2. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
3. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
4. Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research
5. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
6. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
7. MichBio Expo Opens in Lansing Next Week
8. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
9. NicOx Opens U.S. Headquarters in New Jersey
10. Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice
11. BioEnergy International Facility Opens in Bay State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):